Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice

This animal study tested orally administered Aureobasidium pullulans-derived beta-glucan in mice fed a high-fat diet for 16 weeks. Compared with high-fat-diet controls, treated mice showed lower blood cholesterol and triglyceride measurements, less liver fat accumulation, lower serum alanine aminotransferase, and higher liver expression of CYP7A1, a gene involved in cholesterol metabolism. These results suggest a possible metabolic effect in this experimental model. They do not establish that the preparation prevents or treats fatty-liver disease in humans, and differences in dose, metabolism, and disease biology limit direct translation.